Delving into the Latest Updates on 18F-αvβ6-Binding-Peptide with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesRespiratory Diseases+ [4]

Active Indication

Brain metastasesmetastatic non-small cell lung cancerNeoplasms+ [5]

Inactive Indication-

Originator Organization

National Cancer Institute

Active Organization

University of California, Davis

National Cancer Institute

National Institutes of Health

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Start Date13 Sep 2022

Sponsor / Collaborator

University of California, Davis

[+1]

NCT04376593

/ Enrolling by invitationEarly Phase 1IIT

18F-αvβ6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection

This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.

Start Date01 May 2020

Sponsor / Collaborator

University of California, Davis

NCT03164486

/ Active, not recruitingEarly Phase 1IIT

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Start Date01 Nov 2016

Sponsor / Collaborator

University of California, Davis

[+1]

100 Clinical Results associated with 18F-αvβ6-Binding-Peptide

Login to view more data

100 Translational Medicine associated with 18F-αvβ6-Binding-Peptide

Login to view more data

100 Patents (Medical) associated with 18F-αvβ6-Binding-Peptide

Login to view more data

1

Literatures (Medical) associated with 18F-αvβ6-Binding-Peptide

15 Feb 2019·Clinical Cancer ResearchQ1 · MEDICINE

Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma

Q1 · MEDICINE

Article

Author: Chew, Helen K. ; Sutcliffe, Julie L. ; Kim, Edward J. ; Davis, Ryan A. ; Hausner, Sven H. ; Foster, Cameron C. ; Daly, Megan E. ; Bold, Richard J. ; Cheuy, Lina Y.

AbstractPurpose:The study was undertaken to develop and evaluate the potential of an integrin αvβ6-binding peptide (αvβ6-BP) for noninvasive imaging of a diverse range of malignancies with PET.Experimental Design:The peptide αvβ6-BP was prepared on solid phase and radiolabeled with 4-[18F]fluorobenzoic acid. In vitro testing included ELISA, serum stability, and cell binding studies using paired αvβ6-expressing and αvβ6-null cell lines. In vivo evaluation (PET/CT, biodistribution, and autoradiography) was performed in a mouse model bearing the same paired αvβ6-expressing and αvβ6-null cell xenografts. A first-in-human PET/CT imaging study was performed in patients with metastatic lung, colon, breast, or pancreatic cancer.Results:[18F]αvβ6-BP displayed excellent affinity and selectivity for the integrin αvβ6 in vitro [IC50(αvβ6) = 1.2 nmol/L vs IC50(αvβ3) >10 μmol/L] in addition to rapid target-specific cell binding and internalization (72.5% ± 0.9% binding and 52.5% ± 1.8%, respectively). Favorable tumor affinity and selectivity were retained in the mouse model and excretion of unbound [18F]αvβ6-BP was rapid, primarily via the kidneys. In patients, [18F]αvβ6-BP was well tolerated without noticeable adverse side effects. PET images showed significant uptake of [18F]αvβ6-BP in both the primary lesion and metastases, including metastasis to brain, bone, liver, and lung.Conclusions:The clinical impact of [18F]αvβ6-BP PET imaging demonstrated in this first-in-human study is immediate for a broad spectrum of malignancies.

100 Deals associated with 18F-αvβ6-Binding-Peptide

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain metastases	Phase 1	United States	University of California, Davis	13 Sep 2022
metastatic non-small cell lung cancer	Phase 1	United States	University of California, Davis	13 Sep 2022
COVID-19	Phase 1	United States	University of California, Davis	01 May 2020
Breast Cancer	Phase 1	United States	National Cancer Institute	01 Nov 2016
Colorectal Cancer	Phase 1	United States	National Cancer Institute	01 Nov 2016
Pancreatic Cancer	Phase 1	United States	National Cancer Institute	01 Nov 2016
Secondary malignant neoplasm of lung	Phase 1	United States	National Cancer Institute	01 Nov 2016
Neoplasms	Phase 1	-	National Institutes of Health	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.


No Data

18F-αvβ6-Binding-Peptide

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation